Xencor, Inc.

Allergan, Inc.

Genentech, Inc.

Syngenta Participations Ag

Amgen Inc.

John R Desjarlais

Matthew J Bernett

Gregory L Moore

Gregory Alan Lazar

Sher Bahadur Karki

Seung Yup Chu

Rumana Rashid

Omid Vafa

Robert J Hayes

Wei Dang

Umesh Muchhal

Rajat Varma

Arthur J Chirino

Aaron Keith Chamberlain

Michael Hedvat

Christine Bonzon

Stephen Kohl Doberstein

Jost G Vielmetter

Sung-Hyung Lee

Alex Nisthal

Bassil I Dahiyat

Jonathan Zalevsky

Juan Diaz

Igor Vostiar

Holly M Horton

John O Richards

Eugene Alexander Zhukovsky

Ke Liu

Duc-Hanh Thi Nguyen

Suzanne Schubbert

Erik Weiking Pong

Nargess Hassanzadeh-Kiabi

Philip W Hammond

Matthew Adam Dragovich

Sean C Yoder

Veronica Gusti Zeng

David F Carmichael

Darian Cash

Sergei A Ezhevsky

Yanbin Liang

Shannon Marshall

Peter C Baciu

David Szymkowski

Jason Guu

Paul Michael Steed

Rene S Hubert

Bao-lu Chen

Adam Zwolak

Lori Kunkel

Anton Filikov

Fei Shen

Yoon Kyung Kim

Steven P Briggs

Peter Luginbuhl

Peter Bernard Heifetz

Jennitte LeAnn Stevens

Olivier Nolan-Stevaux

Fouad Moussa

Joseph Erhardt

Jamal El Yazal

Theresa McDevitt

Dilki Wickramarachchi

Pankaj Seth

Chad Borchert

Matthew S Faber

Kendra N Avery

Dilki Wickramarachichi

Eric Chang

Jing Qi

Bipin Dalmia

Patrick Holder

Malu Lourdes G Tansey

Christine Huang

Greg Del Val

Adam Read Thomason

Raphael Clynes

Maria D Barbosa

Umesh S Muchhal

Mercedesz Balazs

Bao-Lu Chen

Sean Christopher Yoder

Greogory Alan Lazar

John Owen Richards

David Forrester Carmichael

Malu Tansey

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains

In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.

Heterodimeric proteins

Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.

Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3

Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

Heterodimeric antibodies that bind CD3 and CLDN6

Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

Anti-CD28 x anti-PSMA antibodies

Provided herein are novel anti-CD28× anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28× anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3× anti-PSMA antibodies) for the treatment of prostate cancers.

The present invention is directed to novel heterodimeric antibodies.

Heterodimeric antibodies that bind CD3 and tumor antigens

The present invention is directed to novel IL-15/IL-15Rα heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15Rα heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15Rα heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.

IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereof

The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.

IL-12 heterodimeric Fc-fusion proteins

The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.

Fc variants with altered binding to FcRn

The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).

Heterodimeric antibodies that bind fibroblast activation protein

The present invention is directed to bispecific, heterodimeric checkpoint antibodies.

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.

Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains

The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

Heterodimeric antibodies that bind CD3 and CD38

The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.

Engineered IL-2 Fc fusion proteins

Growing community of inventors

Pasadena, CA, United States of America

John R Desjarlais